PT Kalbe Farma Tbk.
PT Kalbe Farma Tbk.
Your view on PTKFY
Overview
What the company does, where it operates, and who runs it.
About PT Kalbe Farma Tbk.
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- Bernadette Ruth Irawati Setiady
- Headquarters
- Gedung KALBE, Jakarta, ID
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- Bernadette Ruth Irawati Setiady
- Headquarters
- Gedung KALBE, Jakarta, ID
PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. The company operates through four divisions: Prescription Pharmaceuticals, Consumer Health, Nutritionals, and Distribution and Logistic.
It offers generic, branded, and licensed drugs, including Brainact, Cefspan, Mycoral, Cernevit, Cravit, Neuralgin, Broadced, Neurotam, Hemapo, and CPG that are distributed to hospitals, pharmacies, and drug stores.
The company also provides over-the-counter drugs; energy drinks, ready-to-drink products, supplements, and other preventive products; and nutritional products for infants, toddlers, children, teenagers, adults, pregnant and lactating women, and elders, as well as for consumers with special medical needs.
In addition, it offers contract services, including clinical study management, bioavailability/bioequivalence studies, and contract analysis to pharmaceutical companies; and animal health products, as well as operates Mitrasana Clinics, a health care service.
Further, the company provides health screening services; operates as an agent and representative for biotechnology products; distributes consumer products, medical equipment, cosmetics, and other trading products; and trades in medical and laboratory equipment and supplies, raw materials for pharmaceutical products, and consumable products for hemodialysis therapy, as well as offers advertising services. PT Kalbe Farma Tbk.
was incorporated in 1966 and is headquartered in Jakarta, Indonesia.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for PT Kalbe Farma Tbk., and the rating behind it. PTKFY last traded at $13.29, 9.2× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for PT Kalbe Farma Tbk.. Starting points for PT Kalbe Farma Tbk.: P/E 9.2, EPS $15954.09, beta 0.10 — an Drug Manufacturers - General name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for PT Kalbe Farma Tbk.. PT Kalbe Farma Tbk. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for PT Kalbe Farma Tbk.. Trailing twelve-month EPS for PT Kalbe Farma Tbk. stands at $15954.09. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for PT Kalbe Farma Tbk.. PT Kalbe Farma Tbk. has reported as a listed company since 2012. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
PT Kalbe Farma Tbk. valued side by side against its closest peers. PT Kalbe Farma Tbk. is measured against Drug Manufacturers - General peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold PT Kalbe Farma Tbk., and how their positions are changing. At a $15.1M market value, institutional positions materially move PT Kalbe Farma Tbk.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by PT Kalbe Farma Tbk. executives and directors. Shares of PT Kalbe Farma Tbk. have traded between $11.44 and $21.16 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming PT Kalbe Farma Tbk.. PT Kalbe Farma Tbk. is a $15.1M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming PT Kalbe Farma Tbk.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for PT Kalbe Farma Tbk.. Coverage tracks PT Kalbe Farma Tbk. within Drug Manufacturers - General (Healthcare). Press releases and market coverage, newest first.